Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for International Journal of Cell Biology, enter your email address in the box below.

International Journal of Cell Biology
Volume 2012, Article ID 908724, 9 pages
http://dx.doi.org/10.1155/2012/908724
Review Article

Altered Gene Expression, Mitochondrial Damage and Oxidative Stress: Converging Routes in Motor Neuron Degeneration

Luisa Rossi,1 Cristiana Valle,2,3 and Maria Teresa Carrì1,3

1Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, 00133 Rome, Italy
2Institute for Cell Biology and Neurobiology, CNR, 00100 Rome, Italy
3IRCCS Fondazione Santa Lucia, 00143 Rome, Italy

Received 13 February 2012; Accepted 15 March 2012

Academic Editor: Giuseppe Filomeni

Copyright © 2012 Luisa Rossi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Saxena and P. Caroni, “Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration,” Neuron, vol. 71, no. 1, pp. 35–48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Strong and P. H. Gordon, “Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum?” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 6, no. 1, pp. 8–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. H. O. Nousiainen, M. Kestilä, N. Pakkasjärvi et al., “Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease,” Nature Genetics, vol. 40, no. 2, pp. 155–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. R. Lunn and C. H. Wang, “Spinal muscular atrophy,” The Lancet, vol. 371, no. 9630, pp. 2120–2133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Sobue, Y. Hashizume, E. Mukai, M. Hirayama, T. Mitsuma, and A. Takahashi, “X-linked recessive bulbospinal neuronopathy. A clinicopathological study,” Brain, vol. 112, part 1, pp. 209–232, 1989. View at Google Scholar · View at Scopus
  6. A. R. La Spada, E. M. Wilson, D. B. Lubahn, A. E. Harding, and K. H. Fischbeck, “Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy,” Nature, vol. 352, no. 6330, pp. 77–79, 1991. View at Publisher · View at Google Scholar · View at Scopus
  7. A. D. Sperfeld, J. Karitzky, D. Brummer et al., “X-linked bulbospinal neuronopathy: Kennedy disease,” Archives of Neurology, vol. 59, no. 12, pp. 1921–1926, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Udd, V. Juvonen, L. Hakamies et al., “High prevalence of Kennedy's disease Western Finland—is the syndrome underdiagnosed?” Acta Neurologica Scandinavica, vol. 98, no. 2, pp. 128–133, 1998. View at Google Scholar · View at Scopus
  9. P. N. Valdmanis, H. Daoud, P. A. Dion, and G. A. Rouleau, “Recent advances in the genetics of amyotrophic lateral sclerosis,” Current Neurology and Neuroscience Reports, vol. 9, no. 3, pp. 198–205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. P. A. Cox and O. W. Sacks, “Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam,” Neurology, vol. 58, no. 6, pp. 956–959, 2002. View at Google Scholar · View at Scopus
  11. B. A. Golomb, E. K. Kwon, S. Koperski, and M. A. Evans, “Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) statin effects study,” Drug Safety, vol. 32, no. 8, pp. 649–661, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. A. Harwood, C. J. McDermott, and P. J. Shaw, “Physical activity as an exogenous risk factor in motor neuron disease (MND): a review of the evidence,” Amyotrophic Lateral Sclerosis, vol. 10, no. 4, pp. 191–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Chiò, G. Benzi, M. Dossena, R. Mutani, and G. Mora, “Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players,” Brain, vol. 128, part 3, pp. 472–476, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Wicks, J. Ganesalingham, C. Collin, M. Prevett, N. P. Leigh, and A. Al-Chalabi, “Three soccer playing friends with simultaneous amyotrophic lateral sclerosis,” Amyotrophic Lateral Sclerosis, vol. 8, no. 3, pp. 177–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. E. J. Kasarskis, J. H. Lindquist, C. J. Coffman et al., “Clinical aspects of ALS in Gulf War Veterans,” Amyotrophic Lateral Sclerosis, vol. 10, no. 1, pp. 35–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Vanacore, P. Cocco, D. Fadda, and M. Dosemeci, “Job strain, hypoxia and risk of amyotrophic lateral sclerosis: results from a death certificate study,” Amyotrophic Lateral Sclerosis, vol. 11, no. 5, pp. 430–434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Chen, M. Richard, D. P. Sandler, D. M. Umbach, and F. Kamel, “Head injury and amyotrophic lateral sclerosis,” American Journal of Epidemiology, vol. 166, no. 7, pp. 810–816, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Schmidt, L. C. Kwee, K. D. Allen, and E. Z. Oddone, “Association of ALS with head injury, cigarette smoking and APOE genotypes,” Journal of the Neurological Sciences, vol. 291, no. 1-2, pp. 22–29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. C. McKee et al., “TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy,” Journal of Neuropathology and Experimental Neurology, vol. 69, no. 9, pp. 918–929, 2010. View at Google Scholar
  20. V. Gallo, H. B. Bueno-De-Mesquita, R. Vermeulen et al., “Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort,” Annals of Neurology, vol. 65, no. 4, pp. 378–385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Kamel, D. M. Umbach, H. Hu et al., “Lead exposure as a risk factor for amyotrophic lateral sclerosis,” Neurodegenerative Diseases, vol. 2, no. 3-4, pp. 195–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. B. R. Brooks, “Risk factors in the early diagnosis of ALS: North American epidemiological studies,” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 1, supplement 1, pp. S19–S26, 2000. View at Google Scholar
  23. C. J. Burns, K. K. Beard, and J. B. Cartmill, “Mortality in chemical workers potentially exposed to 2,4-dichlorophenoxyacetic acid (2,4-D) 1945-94: an update,” Occupational and Environmental Medicine, vol. 58, no. 1, pp. 24–30, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. N. A. Sutedja, J. H. Veldink, K. Fischer et al., “Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review,” Amyotrophic Lateral Sclerosis, vol. 10, no. 5-6, pp. 302–309, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Cozzolino and M. T. Carri, “Mitochondrial dysfunction in ALS,” Progress in Neurobiology, vol. 97, no. 2, pp. 54–66, 2012. View at Google Scholar
  26. M. Hayashi, S. Araki, N. Arai et al., “Oxidative stress and disturbed glutamate transport in spinal muscular atrophy,” Brain and Development, vol. 24, no. 8, pp. 770–775, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Wan, E. Ottinger, S. Cho, and G. Dreyfuss, “Inactivation of the SMN complex by oxidative stress,” Molecular Cell, vol. 31, no. 2, pp. 244–254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. E. A. Schon and S. Przedborski, “Mitochondria: the next (Neurode) generation,” Neuron, vol. 70, no. 6, pp. 1033–1053, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Berger, J. A. Mayr, D. Meierhofer et al., “Severe depletion of mitochondrial DNA in spinal muscular atrophy,” Acta Neuropathologica, vol. 105, no. 3, pp. 245–251, 2003. View at Google Scholar · View at Scopus
  30. S. Jongpiputvanich, T. Sueblinvong, and T. Norapucsunton, “Mitochondrial respiratory chain dysfunction in various neuromuscular diseases,” Journal of Clinical Neuroscience, vol. 12, no. 4, pp. 426–428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Acsadi, I. Lee, X. Li et al., “Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy,” Journal of Neuroscience Research, vol. 87, no. 12, pp. 2748–2756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Voigt, K. Meyer, O. Baum, and D. Schümperli, “Ultrastructural changes in diaphragm neuromuscular junctions in a severe mouse model for Spinal Muscular Atrophy and their prevention by bifunctional U7 snRNA correcting SMN2 splicing,” Neuromuscular Disorders, vol. 20, no. 11, pp. 744–752, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Ranganathan, G. G. Harmison, K. Meyertholen, M. Pennuto, B. G. Burnett, and K. H. Fischbeck, “Mitochondrial abnormalities in spinal and bulbar muscular atrophy,” Human Molecular Genetics, vol. 18, no. 1, pp. 27–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. A. M. J. Beauchemin, B. Gottlieb, L. K. Beitel, Y. A. Elhaji, L. Pinsky, and M. A. Trifiro, “Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy,” Brain Research Bulletin, vol. 56, no. 3-4, pp. 285–297, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Malaspina, N. Kaushik, and J. de Belleroche, “Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays,” Journal of Neurochemistry, vol. 77, no. 1, pp. 132–145, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. C. W. Lederer, A. Torrisi, M. Pantelidou, N. Santama, and S. Cavallaro, “Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis,” BMC Genomics, vol. 8, article 26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Tanaka et al., “Neuropathology and omics in motor neuron diseases,” Neuropathology. In press. View at Publisher · View at Google Scholar
  38. M. R. Vargas, M. Pehar, P. J. Díaz-Amarilla, J. S. Beckman, and L. Barbeito, “Transcriptional profile of primary astrocytes expressing ALS-linked mutant SOD1,” Journal of Neuroscience Research, vol. 86, no. 16, pp. 3515–3525, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. J. L. Gonzalez de Aguilar, C. Niederhauser-Wiederkehr, B. Halter et al., “Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model,” Physiological Genomics, vol. 32, no. 2, pp. 207–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. P. F. Pradat et al., “Muscle gene expression is a marker of amyotrophic lateral sclerosis severity,” Neuro-Degenerative Diseases, vol. 9, no. 1, pp. 38–52, 2012. View at Google Scholar
  41. C. Y. Wu, D. Whye, L. Glazewski et al., “Proteomic assessment of a cell model of spinal muscular atrophy,” BMC Neuroscience, vol. 12, article 25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. R. N. Saha and K. Pahan, “HATs and HDACs in neurodegeneration: A tale of disconcerted acetylation homeostasis,” Cell Death and Differentiation, vol. 13, no. 4, pp. 539–550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Petri, M. Kiaei, K. Kipiani et al., “Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis,” Neurobiology of Disease, vol. 22, no. 1, pp. 40–49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. M. E. Cudkowicz, P. L. Andres, S. A. Macdonald et al., “Phase 2 study of sodium phenylbutyrate in ALS,” Amyotrophic Lateral Sclerosis, vol. 10, no. 2, pp. 99–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Sugai, Y. Yamamoto, K. Miyaguchi et al., “Benefit of valproic acid in suppressing disease progression of ALS model mice,” European Journal of Neuroscience, vol. 20, no. 11, pp. 3179–3183, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. H. L. Feng, Y. Leng, C. H. Ma, J. Zhang, M. Ren, and D. M. Chuang, “Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model,” Neuroscience, vol. 155, no. 3, pp. 567–572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. E. Yoo and C. P. Ko, “Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis,” Experimental Neurology, vol. 231, no. 1, pp. 147–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. S. H. Kim, N. P. Shanware, M. J. Bowler, and R. S. Tibbetts, “Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA,” The Journal of Biological Chemistry, vol. 285, no. 44, pp. 34097–34105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. L. E. Kernochan, M. L. Russo, N. S. Woodling et al., “The role of histone acetylation in SMN gene expression,” Human Molecular Genetics, vol. 14, no. 9, pp. 1171–1182, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Hahnen, I. Y. Eyüpoglu, L. Brichta et al., “In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy,” Journal of Neurochemistry, vol. 98, no. 1, pp. 193–202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. A. M. Avila, B. G. Burnett, A. A. Taye et al., “Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy,” Journal of Clinical Investigation, vol. 117, no. 3, pp. 659–671, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Riessland, L. Brichta, E. Hahnen, and B. Wirth, “The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells,” Human Genetics, vol. 120, no. 1, pp. 101–110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Rak, B. D. Lechner, C. Schneider, H. Drexl, M. Sendtner, and S. Jablonka, “Valproic acid blocks excitability in SMA type I mouse motor neurons,” Neurobiology of Disease, vol. 36, no. 3, pp. 477–487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. H. R. Fuller, N. T. Man, L. T. Lam, V. A. Shamanin, E. J. Androphy, and G. E. Morris, “Valproate and bone loss: iTRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells,” Journal of Proteome Research, vol. 9, no. 8, pp. 4228–4233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. M. C. Evans, J. J. Cherry, E. J. Androphy et al., “Differential regulation of the SMN2 gene by individual HDAC proteins,” Biochemical and Biophysical Research Communications, vol. 414, no. 1, pp. 25–30, 2011. View at Google Scholar
  56. M. Minamiyama, M. Katsuno, H. Adachi et al., “Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy,” Human Molecular Genetics, vol. 13, no. 11, pp. 1183–1192, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. S. L. Berger, “The complex language of chromatin regulation during transcription,” Nature, vol. 447, no. 7143, pp. 407–412, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. O. Tapia, R. Bengoechea, M. T. Berciano, and M. Lafarga, “Nucleolar targeting of coilin is regulated by its hypomethylation state,” Chromosoma, vol. 119, no. 5, pp. 527–540, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Tripsianes, “Structural basis for dimethylarginine recognition by the Tudor domains of human SMN and SPF30 proteins,” Nature Structural & Molecular Biology, vol. 18, no. 12, pp. 1414–1420, 2011. View at Google Scholar
  60. G. B. Gonsalvez, L. Tian, J. K. Ospina, F. M. Boisvert, A. I. Lamond, and A. G. Matera, “Two distinct arginine methyltransferases are required for biogenesis of Sm-class ribonucleoproteins,” Journal of Cell Biology, vol. 178, no. 5, pp. 733–740, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Hauke, M. Riessland, S. Lunke et al., “Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition,” Human Molecular Genetics, vol. 18, no. 2, pp. 304–317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Bäumer, O. Ansorge, M. Almeida, and K. Talbot, “The role of RNA processing in the pathogenesis of motor neuron degeneration,” Expert Reviews in Molecular Medicine, vol. 12, p. e21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Corcia, W. Camu, J. Praline, P. H. Gordon, P. Vourch, and C. Andres, “The importance of the SMN genes in the genetics of sporadic ALS,” Amyotrophic Lateral Sclerosis, vol. 10, no. 5-6, pp. 436–440, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Piao, T. Hashimoto, S. Takahama et al., “Survival motor neuron (SMN) protein in the spinal anterior horn cells of patients with sporadic amyotrophic lateral sclerosis,” Brain Research, vol. 1372, pp. 152–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Dejesus-Hernandez et al., “Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS,” Neuron, vol. 72, no. 2, pp. 245–256, 2011. View at Google Scholar
  66. A. E. Renton et al., “A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD,” Neuron, vol. 72, no. 2, pp. 257–268, 2011. View at Google Scholar
  67. M. Wojciechowska and W. J. Krzyzosiak, “Cellular toxicity of expanded RNA repeats: focus on RNA foci,” Human Molecular Genetics, vol. 20, no. 19, pp. 3811–3821, 2011. View at Google Scholar
  68. G. Sicot, G. Gourdon, and M. Gomes-Pereira, “Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges,” Human Molecular Genetics, vol. 20, no. 2, pp. R116–R123, 2011. View at Google Scholar
  69. E. Buratti, A. Brindisi, M. Giombi, S. Tisminetzky, Y. M. Ayala, and F. E. Baralle, “TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing,” The Journal of Biological Chemistry, vol. 280, no. 45, pp. 37572–37584, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. O. A. Sofola, P. Jin, Y. Qin et al., “RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a drosophila model of FXTAS,” Neuron, vol. 55, no. 4, pp. 565–571, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. M. J. Hitchler and F. E. Domann, “An epigenetic perspective on the free radical theory of development,” Free Radical Biology and Medicine, vol. 43, no. 7, pp. 1023–1036, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. M. J. Hitchler and F. E. Domann, “Metabolic defects provide a spark for the epigenetic switch in cancer,” Free Radical Biology and Medicine, vol. 47, no. 2, pp. 115–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. B. Langley, M. A. D'Annibale, K. Suh et al., “Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21waf1/cip1 in cell cycle-independent neuroprotection,” Journal of Neuroscience, vol. 28, no. 1, pp. 163–176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Doyle and F. A. Fitzpatrick, “Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function,” The Journal of Biological Chemistry, vol. 285, no. 23, pp. 17417–17424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Hnilicová, S. Hozeifi, E. Dušková, J. Icha, T. Tománková, and D. Staněk, “Histone deacetylase activity modulates alternative splicing,” PLoS ONE, vol. 6, no. 2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. I. Rahman, J. Marwick, and P. Kirkham, “Redox modulation of chromatin remodeling: Impact on histone acetylation and deacetylation, NF-κB and pro-inflammatory gene expression,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1255–1267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. Q. Li, C. V. Velde, A. Israelson et al., “ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 49, pp. 21146–21151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. D. Bergemalm, K. Forsberg, P. Andreas Jonsson et al., “Changes in the spinal cord proteome of an amyotrophic lateral sclerosis murine model determined by differential in-gel electrophoresis,” Molecular and Cellular Proteomics, vol. 8, no. 6, pp. 1306–1317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Massignan, F. Casoni, M. Basso et al., “Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse,” Biochemical and Biophysical Research Communications, vol. 353, no. 3, pp. 719–725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Maracchioni, A. Totaro, D. F. Angelini et al., “Mitochondrial damage modulates alternative splicing in neuronal cells: Implications for neurodegeneration,” Journal of Neurochemistry, vol. 100, no. 1, pp. 142–153, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. S. C. Lenzken, V. Romeo, F. Zolezzi et al., “Mutant SOD1 and mitochondrial damage alter expression and splicing of genes controlling neuritogenesis in models of neurodegeneration,” Human Mutation, vol. 32, no. 2, pp. 168–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Brunet, L. B. Sweeney, J. F. Sturgill et al., “Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase,” Science, vol. 303, no. 5666, pp. 2011–2015, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. Z. Lu, X. Xu, X. Hu et al., “PGC-1α regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload,” Antioxidants and Redox Signaling, vol. 13, no. 7, pp. 1011–1022, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Aquilano, P. Vigilanza, S. Baldelli, B. Pagliei, G. Rotilio, and M. R. Ciriolo, “Peroxisome proliferator-activated receptor γ co-activator 1 α (PGC-1α) and sirtuin 1 (SIRT1) reside in mitochondria: possible direct function in mitochondrial biogenesis,” The Journal of Biological Chemistry, vol. 285, no. 28, pp. 21590–21599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. J. H. Lim, Y. M. Lee, Y. S. Chun, J. Chen, J. E. Kim, and J. W. Park, “Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha.,” Molecular cell, vol. 38, no. 6, pp. 864–878, 2010. View at Google Scholar · View at Scopus
  86. E. M. Dioum, R. Chen, M. S. Alexander et al., “Regulation of hypoxia-inducible factor 2α signaling by the stress-responsive deacetylase sirtuin 1,” Science, vol. 324, no. 5932, pp. 1289–1293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. I. Mattagajasingh, C. S. Kim, A. Naqvi et al., “SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 37, pp. 14855–14860, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. Y. Yang, W. Fu, J. Chen et al., “SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress,” Nature Cell Biology, vol. 9, no. 11, pp. 1253–1262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. M. K. Han, E. K. Song, Y. Guo, X. Ou, C. Mantel, and H. E. Broxmeyer, “SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization,” Cell Stem Cell, vol. 2, no. 3, pp. 241–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Wang, M. Nguyen, F. X. F. Qin, and Q. Tong, “SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction,” Aging Cell, vol. 6, no. 4, pp. 505–514, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. E. L. Bell, B. M. Emerling, S. J. H. Ricoult, and L. Guarente, “SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production,” Oncogene, vol. 30, no. 26, pp. 2986–2996, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Tao, M. C. Coleman, J. D. Pennington et al., “Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress,” Molecular Cell, vol. 40, no. 6, pp. 893–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. Y. Chen, J. Zhang, Y. Lin et al., “Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS,” EMBO Reports, vol. 12, no. 6, pp. 534–541, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. W. C. Hallows, W. Yu, B. C. Smith et al., “Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction,” Molecular Cell, vol. 41, no. 2, pp. 139–149, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. B. H. Ahn, H. S. Kim, S. Song et al., “A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14447–14452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. D. B. Lombard, F. W. Alt, H. L. Cheng et al., “Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation,” Molecular and Cellular Biology, vol. 27, no. 24, pp. 8807–8814, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Someya, W. Yu, W. C. Hallows et al., “Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction,” Cell, vol. 143, no. 5, pp. 802–812, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. M. C. Haigis, R. Mostoslavsky, K. M. Haigis et al., “SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic β cells,” Cell, vol. 126, no. 5, pp. 941–954, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Nakagawa, D. J. Lomb, M. C. Haigis, and L. Guarente, “SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle,” Cell, vol. 137, no. 3, pp. 560–570, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Zhong, A. D'Urso, D. Toiber et al., “The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1α,” Cell, vol. 140, no. 2, pp. 280–293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. O. Vakhrusheva, C. Smolka, P. Gajawada et al., “Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice,” Circulation Research, vol. 102, no. 6, pp. 703–710, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. L. G. Bilsland, E. Sahai, G. Kelly, M. Golding, L. Greensmith, and G. Schiavo, “Deficits in axonal transport precede ALS symptoms in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 47, pp. 20523–20528, 2010. View at Publisher · View at Google Scholar · View at Scopus